Table 3.

Randomized controlled trials investigating the effects of raloxifene augmentation therapy on symptoms in men and women with SSD

Study	N	Sex	Menopause status	Daily dose (mg)	Treatment duration (weeks)	Results
Kulkarni et al. (2010) [64]	22	F	Postmenopausal	60	12	No differences in PANSS symptom scores between groups.
Kulkarni et al. (2010) [64]	26	F	Postmenopausal	120	12	Reduced PANSS total and general symptoms in raloxifene vs. placebo group, no difference in PANSS positive and negative symptoms.
Usall et al. (2011) [65]	33	F	Postmenopausal	60	12	Reduced PANSS negative, positive, and general symptoms in raloxifene vs. placebo group.
Kianimehr et al. (2014) [66]	46	F	Postmenopausal	120	8	Reduced PANSS positive symptoms in raloxifene vs. placebo group, no difference in PANSS total, negative, and general symptoms.
Weickert et al. (2015) [67]	79	M, F	Unknown, age range 18–51	120	6	No differences in PANSS symptom scores between groups.
Kulkarni et al. (2016) [68]	56	F	Peri- and postmenopausal	120	12	Reduced PANSS total and general symptoms in raloxifene vs. placebo group, no difference in PANSS positive and negative symptoms.
Usall et al. (2016) [55]	70	F	Postmenopausal	60	24	Reduced PANSS total, negative, and general symptoms in raloxifene vs. placebo group, no difference in PANSS positive symptoms.
Weiser et al. (2017) [69]	200	F	Postmenopausal	120	16	Increased PANSS total, positive, negative, and general symptoms in raloxifene vs. placebo group.

PANSS Positive and Negative Syndrome Scale, F female, M male